1 / 22

Diabetes Prevention for a Heterogeneous Population

Diabetes Prevention for a Heterogeneous Population. Richard Arakaki , M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John A. Burns School of Medicine September 30, 2011. Type 2 Diabetes Prevention: A Few Questions.

hyunki-noh
Télécharger la présentation

Diabetes Prevention for a Heterogeneous Population

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Diabetes Prevention for a Heterogeneous Population Richard Arakaki, M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John A. Burns School of Medicine September 30, 2011

  2. Type 2 Diabetes Prevention: A Few Questions • UNEQUIVOCALLY SHOWN TO BE PREVENTED AND/OR DELAYED! • How should we identify people at-risk? • What interventions are appropriate? • How do we implement the interventions?

  3. Da Qing IGT and Diabetes Study • Screened 110,660 persons in Da Qing, China for IGT • Randomized 577 persons with IGT at 33 local health centers • Four arm study over 6 years (group intervention for weight loss) • Diet (modest weight reduction due to low BMI) • Exercise • Diet + Exercise • Control Pan et al. Diabetes Care 1997;20:537-44

  4. Da Qing IGT and Diabetes Study Mean change in BMI for intervention -0.69; Control -0.34 Pan et al. Diabetes Care 1997;20:537-44 a Adjusted for BMI and fasting glucose

  5. Diabetes Prevention Program • Primary Goal: • To prevent or delay the development of type 2 diabetes in persons with impaired glucose tolerance (IGT) • Study Interventions: Randomized (3,819 people) Standard lifestyle teaching Intensive Lifestyle (1079 people) Placebo (1082 people) Metformin (1073 people) Troglitazone 585 people Until 6/98

  6. Incidence of Diabetes Placebo (n=1082) Metformin (n=1073, p<0.001 vs. Placebo) Lifestyle (n=1079, p<0.001 vs. Metformin , p<0.001 vs. Placebo) Risk reduction 31% by metformin 58% by lifestyle N Engl J Med 346:393-403, 2002

  7. Effect of Treatment on Incidence of Diabetes PlaceboMetforminLifestyle Incidence of diabetes 11.0% 7.8% 4.8% (percent per year) Reduction in incidence ---- 31%58% compared with placebo/metformin 39% Number needed to treat ---- 13.9 6.9 to prevent 1 case in 3 years N Engl J Med 346:393-403, 2002

  8. Diabetes Incidence Rates by Ethnicity 71% 51% N Engl J Med 346:393-403, 2002

  9. Diabetes Incidence Rates by Fasting Glucose Fasting Plasma Glucose: mg/dl (mmol/l) N Engl J Med 346:393-403, 2002

  10. Diabetes Incidence Rates by 2-hr Glucose 2-Hour Plasma Glucose (mg/dl) N Engl J Med 346:393-403, 2002

  11. DPPOS Incidence of Diabetes DPP Research Group. Lancet. 2009; 374:1677-1686 (Figure 4)

  12. DPPOS Diabetes Risk Reduction Delay in diabetes onset after 10 years follow-up: 4 years for Lifestyle; 34% lower risk 2 years for Metformin; 18% lower risk The key factors for lower rate of diabetes development for lifestyle and metformin. Weight loss is the predominant factor; 16% RR per kg weight loss Metformin compliance

  13. Summary of Treatment Effects • Lifestyle intervention was beneficial regardless of ethnicity, age, BMI, or sex • The efficacy of lifestyle relative to metformin was greater in older persons and in those with lower BMI • The efficacy of metformin relative to placebo was greater in those with higher baseline fasting glucose and BMI

  14. Cumulative incidence of DM during follow-up in China Da Qing Diabetes Prevention Outcome Study Li et al. Lancet 2008;317:1783-89

  15. Lifestyle Intervention/Prevention DM Asian Studies Knowler W et al, N Engl J Med 2002;346:393-403, 2002; Pan XR et al, Diabetes Care 1997;20:537-544; Kosaka Diabetes Res Clin Pract 2005;67:152-62K et al,; Ramachandran A et al, Diabetologia 2006;49:289-97; Saito T et al Arch Intern Med 2011;171:1352-60.

  16. Zensharen Study: Cumulative Diabetes Incidence by baseline glucose tolerance status Saito T et al Arch Intern Med 2011;171:1352-60.

  17. Medication DM Prevention Studies in Asians Knowler W et al, N Engl J Med 2002;346:393-403, 2002; Ramachandran A et al, Diabetologia 2009;52:1019-26; Li, CL et al Diabetic Med 1999;16:477-481; DREAM Trial Investigators Lancet 2006;368:1096-1105; Kawamori R et al, Lancet 2009;373:1607-14.

  18. Genetics Risk for Diabetes • 10% Estimate of diabetes associated with known genetic risk (Jablonski K et al Diabetes 2010) • Primarily related to beta-cell function • Overall genetic markers (SNPs by GWAS) associated with increased rates of DM are similar across all ethnic groups (Europeans, Asians, etc; Tan JT et al, J ClinEndocrinolMetab 2010;95:390-397). • Allele frequency may reduce usefulness of SNPs for screening at-risk individuals • TCF7L2 Polymorphisms and progression to diabetes in the Diabetes Prevention Program (N Engl J Med, July 2006); • high risk SNP but still responsive to lifestyle intervention

  19. Type 2 Diabetes Prevention: A Few Answers? • How should we identify people at-risk? • Pathophysiologicand physical characteristics • low insulinogenic index (beta cell function) • high HOMA IR (insulin resistance) • higher BS levels; fasting > 110 mg/dl; A1c>6.0% • Zensharen Study- need for OGTT • GWAS; look for multiple SNPs, additive risk

  20. Type 2 Diabetes Prevention: A Few Answers? • What interventions are appropriate? • ANY effective Weight loss interventions • Lower BMI group • More weight loss-greater effect • Effective Exercise interventions • 150 min/week or more? • Medications • Metformin 250 BID/TID (lower doses) • TZDs at high dose • Alpha-glucosidase inhibitors-preferred?

  21. Type 2 Diabetes Prevention: A Few Answers? • How do we implement the interventions? • Community-Based Interventions • Physicians/physician’s groups • Medicare/ Other Insurers • Government-Federal/State • Are we even there yet?

  22. Thank you for your attention

More Related